Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H31NO4 |
Molecular Weight | 373.4858 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@@](COCC1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C2=CC=CC=C2
InChI
InChIKey=MVKIWCDXKCUDEH-QFIPXVFZSA-N
InChI=1S/C22H31NO4/c1-7-22(23(2)3,18-11-9-8-10-12-18)16-27-15-17-13-19(24-4)21(26-6)20(14-17)25-5/h8-14H,7,15-16H2,1-6H3/t22-/m0/s1
Molecular Formula | C22H31NO4 |
Molecular Weight | 373.4858 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Fedotozine [(1R)-1-phenyl-1-[(3,4,5-trimethoxy) benzyloxymethyl]-N,N- dimethyl-n-propylamine, (2S,3S-tartrate], derived from the arylacetamide series, is an opioid drug which acts as a selective agonist for kappa(1a)-opioid receptor. Pharmacological studies have shown that fedotozine exerts a peripheral antinociceptive action, comparable with that of other kappa-agonists. Results of Phase III trials of fedotozine against irritable bowel syndrome and dyspepsia have ultimately been disappointing and was lack of efficacy in subsequent studies.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P41145 Gene ID: 4986.0 Gene Symbol: OPRK1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11116283 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
70 mg 3 times / day multiple, oral (unknown) Highest studied dose Dose: 70 mg, 3 times / day Route: oral Route: multiple Dose: 70 mg, 3 times / day Sources: |
unhealthy n = 31 Health Status: unhealthy Condition: Nonulcer dyspepsia Sex: M+F Food Status: UNKNOWN Population Size: 31 Sources: |
Other AEs: The... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
The | 70 mg 3 times / day multiple, oral (unknown) Highest studied dose Dose: 70 mg, 3 times / day Route: oral Route: multiple Dose: 70 mg, 3 times / day Sources: |
unhealthy n = 31 Health Status: unhealthy Condition: Nonulcer dyspepsia Sex: M+F Food Status: UNKNOWN Population Size: 31 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of fedotozine on gastrointestinal motility in dogs: mechanism of action and related pharmacokinetics. | 1990 Aug |
|
Differential effects of fedotozine compared to other kappa agonists on diuresis in rats. | 1996 Dec |
|
Novel developments with selective, non-peptidic kappa-opioid receptor agonists. | 1997 Oct |
|
Peripheral opioids for functional GI disease: a reappraisal. | 2006 |
|
Inhibitory effect of the selective serotonin 5-HT₃ receptor antagonist ramosetron on duodenal acidification-induced gastric hypersensitivity in rats. | 2014 May 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://adisinsight.springer.com/drugs/800001140
Unknown
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1981581
Curator's Comment: Fedotozine showed submicromolar affinity for opiate receptors with a weak specificity for the mu-receptors in guinea-pig brain and myenteric plexus preparations
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:18:47 GMT 2023
by
admin
on
Fri Dec 15 17:18:47 GMT 2023
|
Record UNII |
F45VW2087W
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Fri Dec 15 17:18:48 GMT 2023 , Edited by admin on Fri Dec 15 17:18:48 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID901318556
Created by
admin on Fri Dec 15 17:18:48 GMT 2023 , Edited by admin on Fri Dec 15 17:18:48 GMT 2023
|
PRIMARY | |||
|
C80580
Created by
admin on Fri Dec 15 17:18:48 GMT 2023 , Edited by admin on Fri Dec 15 17:18:48 GMT 2023
|
PRIMARY | |||
|
C067749
Created by
admin on Fri Dec 15 17:18:48 GMT 2023 , Edited by admin on Fri Dec 15 17:18:48 GMT 2023
|
PRIMARY | |||
|
m1155
Created by
admin on Fri Dec 15 17:18:48 GMT 2023 , Edited by admin on Fri Dec 15 17:18:48 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB07524MIG
Created by
admin on Fri Dec 15 17:18:48 GMT 2023 , Edited by admin on Fri Dec 15 17:18:48 GMT 2023
|
PRIMARY | |||
|
123618-00-8
Created by
admin on Fri Dec 15 17:18:48 GMT 2023 , Edited by admin on Fri Dec 15 17:18:48 GMT 2023
|
PRIMARY | |||
|
F45VW2087W
Created by
admin on Fri Dec 15 17:18:48 GMT 2023 , Edited by admin on Fri Dec 15 17:18:48 GMT 2023
|
PRIMARY | |||
|
Fedotozine
Created by
admin on Fri Dec 15 17:18:48 GMT 2023 , Edited by admin on Fri Dec 15 17:18:48 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106275
Created by
admin on Fri Dec 15 17:18:48 GMT 2023 , Edited by admin on Fri Dec 15 17:18:48 GMT 2023
|
PRIMARY | |||
|
6526
Created by
admin on Fri Dec 15 17:18:48 GMT 2023 , Edited by admin on Fri Dec 15 17:18:48 GMT 2023
|
PRIMARY | |||
|
100000081769
Created by
admin on Fri Dec 15 17:18:48 GMT 2023 , Edited by admin on Fri Dec 15 17:18:48 GMT 2023
|
PRIMARY | |||
|
6918160
Created by
admin on Fri Dec 15 17:18:48 GMT 2023 , Edited by admin on Fri Dec 15 17:18:48 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |